Achillion Pharmaceuticals

INVESTORS

Press Releases

 
Press Releases
  Date Title View
Jul 10, 2017
NEW HAVEN, Conn., July 10, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), the leader in complement alternative pathway therapeutics, today announced that Mingjun Huang, Ph.D., is being promoted to Senior Vice President and Head of Research. With this promotion, Dr. Huang broadens her ...
PDF
Jun 15, 2017
NEW HAVEN, Conn., June 15, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Tuesday, June 20, 2017 at 2:...
PDF
Jun 5, 2017
NEW HAVEN, Conn., June 05, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the Achillion management team will present a corporate overview at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017, at 4:30 p.m. ET at the Grand Hyatt Ho...
PDF
May 4, 2017
NEW HAVEN, Conn., May 04, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2017. For the first quarter of 2017, the Company reported a net loss of $20.2 million or $0.15 per share, compared with a net loss of $18.1 millio...
PDF
May 2, 2017
NEW HAVEN, Conn., May 02, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 42nd Annual Health Care Conference on Thursday, May 4, 2017, at 10:...
PDF
Apr 22, 2017
AMSTERDAM, the Netherlands, April 22, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the presentation of updated results from the ongoing phase 2 ‘604 Study' being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies (Janssen). These res...
PDF
Apr 6, 2017
NEW HAVEN, Conn., April 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced initiation of patient dosing in a Phase 2 open-label study of ACH-4471, Achillion's first orally-administered, small molecule factor D inhibitor, for patients with paroxysmal nocturnal hemog...
PDF
Mar 21, 2017
NEW HAVEN, Conn., March 21, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent to Achillion resulting from its complement factor D research program. U.S. Patent No. 9,598,446 has been granted wi...
PDF
Feb 28, 2017
Three-year study commenced to include up to 400 patientsNatural history studies track course of a disease over time; can inform and support development and approval of new treatments for patientsC3 glomerulopathy currently has no cure or approved treatment; affects about 8,000 people acr...
PDF
Feb 23, 2017
Complement factor D inhibitor program on track for initiation of ACH-4471 phase II trial for treatment-naïve PNH patients during the first half of 2017Expanding complement platform includes internally discovered next-generation oral factor D inhibitors with the goal of advancing at least one into clinical...
PDF
1
...
NextLast